Anixa Biosciences, Inc.

twitter logo
Nasdaq: ANIX
  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
    • Scientific Advisors
    • Breast Cancer Clinical Advisory Board
    • Cancer Business Advisory Board
  • Technologies
    • CAR-T
      • Introduction
      • Markets
      • Science
      • Collaborators
    • Cancer Vaccines
      • Introduction
      • Markets
      • Science
      • Collaborators
      • Breast Cancer Clinical Advisory Board
  • Pipeline
  • Investors
    • Overview
    • News Releases
    • The Future of Cancer Immunotherapy & Women’s Health
    • Events & Presentations
      • Events
      • Corporate Presentation
    • Stock Information
      • Quote
      • Charts
      • Historical Data
      • Analyst Coverage
    • SEC Filings
      • SEC Filings
    • Financial Reports
      • Annual Reports
      • Quarterly Reports
    • Corporate Governance
      • Governance Documents
      • Committee Charters
  • News
    • Press Releases
    • Anixa In The News
    • Publications
    • YouTube Channel
  • Contact Us

Annual Reports

Investors

Investors

  • Overview
  • News Releases
  • The Future of Cancer Immunotherapy & Women’s Health
  • Events & Presentations
    • Events
    • Corporate Presentation
  • Stock Info
    • Quote
    • Charts
    • Historical Data
    • Analyst Coverage
  • SEC Filings
  • Financial Reports
    • Annual Reports
    • Quarterly Reports
  • Governance
    • Governance Documents
    • Committee Charters
  • Investor Resources
    • Investor FAQs
    • Email Alerts
    • Fact Sheet
    • Contact IR
    • RSS News Feed
  • Financial Reports

  • Annual Reports
  • Quarterly Reports
Filter Filings:
Date Form Description Docs XBRL Pages
12/08/16 10-K/A Annual report pursuant to Section 13 and 15(d)
Related Documents
EX-31.1
EX-31.2
EX-32.1
EX-32.2
HTML PDF XBRL Viewer XLS XBRL Files 85
12/07/16 10-K Annual report pursuant to Section 13 and 15(d)
Related Documents
EX-4.2
EX-10.19
EX-10.20
EX-10.21
EX-21
EX-23.1
EX-31.1
EX-31.2
EX-32.1
EX-32.2
EX-99.1
EX-99.2
EX-99.1
HTML PDF 138
12/23/15 10-K Annual report pursuant to Section 13 and 15(d)
Related Documents
EX-21
EX-23.1
EX-31.1
EX-31.2
EX-32.1
EX-32.2
HTML PDF XBRL Viewer XLS XBRL Files 97
01/29/15 10-K/A Annual report pursuant to Section 13 and 15(d)
Related Documents
EX-23.1
EX-31.1
EX-31.2
EX-32.1
EX-32.2
HTML PDF 15
01/29/15 10-K Annual report pursuant to Section 13 and 15(d)
Related Documents
EX-21
EX-31.1
EX-31.2
EX-32.1
EX-32.2
HTML PDF XBRL Viewer XLS XBRL Files 101
04/16/14 10-K/A Annual report pursuant to section 13 and 15(d)
Related Documents
EX-31
EX-31
EX-32
EX-32
HTML PDF 41
01/17/14 10-K/A Annual report pursuant to section 13 and 15(d) HTML PDF XBRL Viewer XLS XBRL Files 6
01/16/14 10-K Annual report pursuant to section 13 and 15(d)
Related Documents
EX-3
EX-21
EX-23
EX-31
EX-31
EX-32
EX-32
HTML PDF 111
08/27/13 ARS Annual report to security holders HTML PDF 108
01/29/13 10-K Annual report pursuant to section 13 and 15(d)
Related Documents
EX-3
EX-10
EX-10
EX-10
EX-10
EX-10
EX-10
EX-10
EX-23
EX-31
EX-31
EX-32
EX-32
HTML PDF XBRL Viewer XLS XBRL Files 244
RSS
  • << Previous
  • 1
  • 2
  • 3
  • 4
  • 5
  • Next >>

Sign up for email Updates

Be The First to Receive Breaking News

Sign Up Now
Logo Itus
twitter logo

Latest News & Events

Mar 2, 2026

Anixa Biosciences to Host 2026 Annual Meeting of Stockholders and Provide Corporate Update Highlighting Recent Clinical and Regulatory Progress

Read More...
Feb 23, 2026

Anixa Biosciences Announces Dr. Jose Conejo-Garcia will Keynote the South Carolina Clinical & Translational Research Institute 2026 Retreat

Read More...
Feb 9, 2026

Anixa Biosciences Reports Encouraging Patient Survival Observations in Ovarian Cancer CAR-T Trial; Achieves Regulatory Approval Enabling Major Dose Escalation

Read More...
Copyrights © 2026 Anixa Biosciences, Inc.. All Rights Reserved.
twitter logo Privacy Policy Terms of Use Disclaimer Sitemap